Catalent Pharma Solutions has completed the second phase of a $5.5 million expansion program at its Kansas City, MO facility, increasing controlled-substance and controlled-temperature storage capabilities for its clinical supply business.
 
The latest expansion includes a new Drug Enforcement Administration (DEA) Schedule I and II controlled substance vault, providing the site with an additional 3,600 sq.-ft. of storage, as well as additional controlled temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations. Also, a new sampling room has been installed, as well as a new emergency generator to ensure the security and integrity of samples in storage.
 
“Catalent customers have benefitted from our integrated analytical, oral solid manufacturing, and clinical supply services which our Kansas City campus has offered continuously for over 18 years,” commented Kevin Economos, General Manager of Clinical Supply Services at the site. “These latest expansions are critical enablers to our customers’ continued growth, that reinforce our comprehensive global network, and enhance Catalent’s role as a market leader in the clinical supply industry.”

This recent expansion concludes a two-year project that also expanded the Kansas City facility’s highly-potent, cytotoxic and cold storage clinical drug packaging capabilities.

The 450,000-sq.-ft. Kansas City facility provides integrated support services, from development and analytical support through to packaging and distribution. The expansions at Kansas City follow the recent announcements of new capabilities and capacity at two of Catalent’s other clinical supply facilities in Philadelphia and Singapore.